E-Town Capital invested in Annoroad Gene Technology (Beijing) Co Ltd (hereinafter referred to as “Annoroad”) through the funds.

Annoroad is a well-known enterprise in the genome industry, and a leading NIPT service provider in China, focusing on the industrial application of next-generation genomics technology in the fields of healthcare and life science research.

The company has its own leading-edge genome sequencing and bioinformatics technology, and has launched the leading desktop high-throughput sequencer NextSeq 550AR and the bio big data platform Anno Cloud.

At present, it has a highly-regarded product system and considerable brand loyalty in sequencing equipment and molecular diagnostic reagents, medical testing and research, scientific research services, gene big data and cloud platform services. It has formed a full industrial chain layout covering the upstream, midstream and downstream of the business and a strong Bio-IT industrialization service capability, which has won praise and recognition from its partners. 

Website: http://www.annoroad.com/